ISSN: 1758-8340

Journal Home

Therapeutic Advances in Medical Oncology Q1 Unclaimed

SAGE Publications Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Therapeutic Advances in Medical Oncology is a journal indexed in SJR in Oncology with an H index of 68. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on oncology, cancer. It has an SJR impact factor of 1,529 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,529.

Type: Journal

Type of Copyright: CC BY-NC

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Oncology (Q1)

Price

1800 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Therapeutic Advances in Medical Oncology

1,529

SJR Impact factor

68

H Index

175

Total Docs (Last Year)

571

Total Docs (3 years)

10526

Total Refs

2480

Total Cites (3 years)

559

Citable Docs (3 years)

4.06

Cites/Doc (2 years)

60.15

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1

Compare this journals

Aims and Scope

Oncology Cancer

Best articles by citations

Management of patients with vulvar cancer: a perspective review according to tumour stage

Health-related quality of life and cancer clinical trials

Taxanes: vesicants, irritants, or just irritating?

Correlation between NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and increased risk of esophageal cancer: evidence from a meta-analysis

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy

Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

Treatment of older patients with colorectal cancer: a perspective review

History and current state of immunotherapy in glioma and brain metastasis

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence

Optimal management of hormone receptor positive metastatic breast cancer in 2016

Current and future options in the management and treatment of uterine sarcoma

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

SHOW MORE ARTICLES

Predictive and prognostic molecular markers for cancer medicine

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy

Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer

New treatment approaches in melanoma: current research and clinical prospects

Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

Review: Systemic therapy for advanced renal cell carcinoma

Isolated hepatic perfusion for patients with liver metastases

Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians

The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events

Prolyl isomerase Pin1 and neurotrophins: a loop that may determine the fate of cells in cancer and neurodegeneration